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Abstract 
Background: Arcobacter species, particularly A. butzleri, but also A. cryaerophilus constitute emerging pathogens 
causing gastroenteritis in humans. However, isolation of Arcobacter may often fail during routine diagnostic proce-
dures due to the lack of standard protocols. Furthermore, defined breakpoints for the interpretation of antimicrobial 
susceptibilities of Arcobacter are missing. Hence, reliable epidemiological data of human Arcobacter infections are 
scarce and lacking for Germany. We therefore performed a 13-month prospective Arcobacter prevalence study in Ger-
man patients.
Results: A total of 4636 human stool samples was included and Arcobacter spp. were identified from 0.85% of 
specimens in 3884 outpatients and from 0.40% of specimens in 752 hospitalized patients. Overall, A. butzleri was the 
most prevalent species (n = 24; 67%), followed by A. cryaerophilus (n = 10; 28%) and A. lanthieri (n = 2; 6%). Whereas 
A. butzleri, A. cryaerophilus and A. lanthieri were identified in outpatients, only A. butzleri could be isolated from sam-
ples of hospitalized patients. Antimicrobial susceptibility testing of Arcobacter isolates revealed high susceptibilities to 
ciprofloxacin, whereas bimodal distributions of MICs were observed for azithromycin and ampicillin.
Conclusions: In summary, Arcobacter including A. butzleri, A. cryaerophilus and A. lanthieri could be isolated in 0.85% 
of German outpatients and ciprofloxacin rather than other antibiotics might be appropriate for antibiotic treatment of 
infections. Further epidemiological studies are needed, however, to provide a sufficient risk assessment of Arcobacter 
infections in humans.
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Background
The genus Arcobacter belongs to the family of Campy-
lobactereaceae as initially proposed by Vandamme 
et  al. [1]. To date, 29 Arcobacter species have been 
identified [2, 3]. The Gram-negative, motile bacte-
ria are aerotolerant and able to grow at temperatures 
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various sources, such as animals, food products of 
animal origin, vegetables and environmental waters 
[4–6]. In animals, Arcobacter infections sometimes 
result in reproductive disorders, mastitis, and diar-
rhea, whereas the bacteria can also be isolated from 
healthy carriers [4]. In humans, severe cases follow-
ing Arcobacter infection have been reported includ-
ing prolonged watery gastroenteritis with abdominal 
cramps, bacteremia, endocarditis and peritonitis [5, 
7, 8]. A.  butzleri followed by A.  cryaerophilus are the 
predominant species isolated from human specimens, 
while human infections with A. skirrowii or A. thereius 
have only been rarely reported [9–11]. Nevertheless, 
the clinical relevance of human Arcobacter infections 
is still under debate. Given that the isolation and iden-
tification of Arcobacter may fail in routine diagnostic 
settings, robust epidemiological data on Arcobacter-
induced morbidities are limited. Thus far, Arcobac-
ter prevalences of 0.2–3.6% have been reported for 
humans [4, 12]. In a recent Belgian study, Arcobac-
ter was the fourth most common pathogenic agent in 
diarrheal outpatients [10]. To date, there are no Arco-
bacter prevalence data for Germany, although since 
2002, Arcobacter species such as A. butzleri and A. cry-
aerophilus have been classified as serious hazards to 
human health by the International Commission on 
Microbiological Specification for Foods [13].
Most infections with Arcobacter appear to be self-
limiting and do not require antimicrobial treatment; 
nevertheless, in cases of severe and persistent symp-
toms antibiotic treatment may be indicated [14]. Sev-
eral classes of antibiotics, such as fluoroquinolones, 
tetracyclines and aminoglycosides have been consid-
ered for treatment of Arcobacter infections [5]. How-
ever, a recent meta-regression analysis revealed an 
emerging resistance of Arcobacter species against vari-
ous antibiotics including fluoroquinolones [15]. There-
fore, the objective of the present prospective study was 
(i) to determine the prevalence of Arcobacter  spp. in 
human stool samples in Germany and (ii) to assess the 
antimicrobial susceptibility patterns of the isolates.
Results
Prevalence of Arcobacter spp. in human stool samples
In the present study, a total of 4636 human stool sam-
ples were included. By using Arcobacter-specific isolation 
procedures, Arcobacter spp. were detected in 33 samples 
(0.85%) obtained from 3884 outpatients and in 3 speci-
mens (0.40%) from 752 hospitalized patients (Table 1). Of 
the 33 isolates, 21 were identified as A. butzleri and 10 as 
A. cryaerophilus by multiplex PCR, while rpoB sequenc-
ing revealed that two of the putative A. butzleri isolates 
belong to the species A. lanthieri. All three Arcobacter 
species were isolated from outpatients samples, whereas 
only A.  butzleri was isolated from hospitalized speci-
mens. Overall, A.  butzleri was the most prevalent spe-
cies, followed by A. cryaerophilus and A. lanthieri.
For a subgroup of the outpatients study population 
(n = 2257), data on other bacterial pathogens were avail-
able. While an enrichment step was used for the isolation 
of Yersinia and Salmonella, the isolation of Campylo-
bacter was  performed without enrichment. Within this 
subgroup Campylobacter spp. (4.39%) were the most fre-
quently detected bacterial pathogens, followed by Salmo-
nella enterica (0.75%), and Yersinia enterocolitica (0.09%) 
(Fig.  1). Notably in this subgroup, a twofold higher 
Table 1 Prevalence of Arcobacter spp. in human stool samples collected from October 2017 to October 2018
Patients No. of samples Arcobacter spp. Identified species
A. butzleri A. cryaerophilus A. lanthieri
Outpatient 3884 0.85% [33] 64% (21/33) 30% (10/33) 6% (2/33)
Hospitalized 752 0.40% [3] 100% (3/3) – –
Total 4636 0.77% [36] 67% (24/36) 28% (10/36) 6% (2/36)
Fig. 1 Prevalence of bacterial pathogens in a subgroup of the study 
population (n = 2257). Black bars: prevalence of Arcobacter spp. 
detected by using Arcobacter specific enrichment culture; grey bars: 
prevalence of bacterial pathogen detected by routine methods
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(0.97%) Arcobacter prevalence was determined by spe-
cific Arcobacter enrichment procedures compared to the 
prevalence determined by the routine diagnostic method 
for Campylobacter without enrichment (0.49%).
Antimicrobial susceptibilities of Arcobacter isolates
For antimicrobial susceptibility testing of human Arco-
bacter isolates, six antibiotics were selected. Overall, our 
results revealed normally distributed minimal inhibi-
tory concentrations (MICs) among Arcobacter spp. for 
erythromycin, ciprofloxacin, gentamicin and tetracy-
cline, while a bimodal distribution for azithromycin and 
ampicillin was apparent (Fig. 2). For erythromycin, MICs 
(ranging from 0.5 to 32.0 µg/ml; Table 2) were distributed 
around the epidemiological cut-off (ECOFF) for C. jejuni 
(4 µg/ml; Fig. 2), while MICs for azithromycin were dis-
tributed above the ECOFF of C. jejuni (0.25 µg/ml; Fig. 2), 
ranging from 0.5 to 64.0 µg/ml (Table 2). Elevated MICs 
for azithromycin (> 8 µg/ml; Fig. 2) were determined for 
50% of A. butzleri and 10% of A. cryaerophilus isolates 
(Table 2). The majority of all isolates (86%; Table 2) dis-
played high susceptibility to ciprofloxacin (MIC ≤ 1  µg/
ml; Fig. 2), whereas MIC ≥ 4 µg/ml were determined for 
2/24 (8%) of A. butzleri and 3/10 (30%) of A. cryaerophi-
lus isolates (Table 2). Only MICs below the ECOFF for C. 
jejuni (2 µg/ml) were determined for gentamicin, with no 
species differences (Fig. 2, Table 2). The MICs for ampi-
cillin were bimodally distributed around the ECOFF of 
C.  jejuni (8 µg/ml; Fig. 2) and 10/24 (42%) of A. butzleri 
and 2/10 (20%) of A. cryaerophilus isolates displayed ele-
vated MICs (> 8 µg/ml; Fig. 2, Table 2). For tetracycline, 
MICs of all Arcobacter spp. isolates were distributed 
around the ECOFF for C. jejuni (1 µg/ml; Fig. 2), whereas 
the MICs determined for both A. lanthieri isolates were 
distributed within the ranges described for the other two 
species (Table 2).
Discussion
Arcobacter prevalence in human stool samples
This is the first prospective study addressing the preva-
lence of Arcobacter in stool samples from outpatients and 
hospitalized patients in Germany by applying an Arco-
bacter-specific detection method. Overall, Arcobacter 
spp. were isolated from 36 out of a total of 4636 (0.77%) 
examined specimens. This isolation rate is in concord-
ance with studies from New Zealand and Belgium, 
where Arcobacter spp. were detected in 0.9% (12/1380) 
and 1.31% (89/6774) of human diarrheal fecal samples 
respectively [10, 20], whereas slightly different preve-
lances (as low as 0.2 or up to 3.6%) were found in other 
studies from Belgium, Turkey, Portugal, India and Chile 
[12, 21–24]. These differences could be attributed to vari-
ous factors, such as patient populations, geographical 
aspects, examined sample sizes, and in particular, to the 
different microbiological methods applied. The impact of 
the detection method has been demonstrated in several 
studies [25–28]. The authors each compared different 
cultural isolation strategies with varying incubation and 
medium conditions revealing differences in Arcobacter 
isolation frequency ranging from 7% to 36%. Notably, our 
study revealed a higher Arcobacter prevalence in an ana-
lyzed subgroup by using Arcobacter-specific enrichment 
(0.97%) than determined by non-specific methods used 
in the three routine laboratories (0.49%). Future studies 
should address whether patients with Arcobacter spp. 
at low quantities that can only be detected by applying 
specific enrichment methods differ clinically from those 
patients in whom the pathogen is easily detected within 
the routine culture-based procedures.
Furthermore, we determined a higher Arcobacter prev-
alence in stool samples of outpatients than of hospital-
ized patients (i.e., 0.85% (33/3884) and 0.40% (3/752), 
respectively). Thus, in most patients, Arcobacter spp. 
most likely do not cause serious infections requiring 
hospitalization. Likewise, in a previous German study, 
patients who were hospitalized for severe gastroenteritis 
(n = 104) were found to be positive mainly for norovirus 
or Campylobacter spp.; in contrast, no Arcobacter was 
isolated by using routine diagnostics [29].
Among the 36 Arcobacter isolates obtained in our 
study, A. butzleri was the most prevalent species (n = 24) 
followed by A.  cryaerophilus (n = 10), which is in line 
with other studies [10, 21, 24]. In addition, to best of our 
knowledge, this is the first report of A.  lanthieri isola-
tion from human specimens (n = 2) which might point 
towards its role as gastrointestinal pathogen. However, 
the applied selective enrichment media as well as the 
multiplex PCR are validated for the detection of the three 
species A. butzleri, A. cryaerophilus and A. skirrowii only, 
and could therefore bias the result according to species 
diversity [16, 18].
Overall, in the analyzed subgroup Arcobacter spp. were 
the second most frequently isolated pathogens (0.97%) 
after Campylobacter spp. (4.39%), followed by Salmonella 
enterica (0.75%). Our results are supported by a previ-
ous study demonstrating Arcobacter spp. as fourth most 
commonly isolated pathogens from diarrheal patients 
(1.31%), after Campylobacter spp. (5.61%), Salmonella 
spp. (2.04%) and C. difficile (1.61%), albeit prevalences of 
the enteropathogens were higher than in our study [10].
Antimicrobial susceptibility
Data regarding antimicrobial susceptibilities of Arco-
bacter spp. are scarce, mainly due to missing standard-
ized protocols and defined breakpoints, which makes it 
difficult to interpret results and to define antimicrobial 
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resistance. In previous studies, MIC results have been 
compared with breakpoints for Enterobacteriaceae or 
Staphylococcus spp. as defined by the Clinical Labora-
tory Standards Institute (CLSI), with breakpoints for 
Campylobacter as defined by the U.S. National Resistance 
Monitoring System criteria or with EUCAST breakpoints 
for Enterobacteriaceae, Campylobacter or non-species 
related breakpoints [5, 30, 31]. In our study, we compared 
the MICs with ECOFFs defined by EUCAST for C. jejuni 








































































































































ECOFF for C. jejuni
Fig. 2 MIC distribution of Arcobacter spp. originating from human stool samples for six antimicrobial agents. The MICs determined by gradient strip 
method were adjusted upwards to the next upper two-fold dilution. Black broken lines: epidemiological cut-offs (ECOFFs) for C. jejuni 
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jejuni ECOFFs appear to apply for Arcobacter as well as 
previously proposed by Riesenberg et  al. [33]. However, 
our data suggest that Arcobacter ECOFFs for erythromy-
cin, tetracycline and azithromycin may be higher than 
those of C. jejuni. All of our isolates displayed MICs for 
azithromycin above the ECOFF of C. jejuni (0.25 µg/ml), 
which, however, is comparable with data from a Belgian 
study [34]. Although erythromycin and azithromycin are 
both macrolides, the bimodal distribution for azithro-
mycin but not for erythromycin was remarkable. Van 
den Abeele et  al. have also detected MICs > 8  µg/ml for 
azithromycin in 50% of A. butzleri isolates, which is in 
line with our results [34]. Likewise, other studies revealed 
elevated MICs for azithromycin in up to 95% of A. but-
zleri and in 20% of A. cryaerophilus strains isolated from 
poultry products [30, 35]. Similar to our results, other 
studies on antimicrobial susceptibility revealed also low 
MICs for Arcobacter spp. to erythromycin whereas some 
studies reported resistance rates up to 62% [5, 36, 37]. 
In contrast to our study, those studies used disc diffu-
sion assays with 15  µg/disc and applied resistance cri-
teria for Enterobacteriaceae according to CLSI 2010. In 
Campylobacter, there is usually cross-resistance between 
azithromycin and erythromycin. Single isolates, however, 
may display susceptibility to erythromycin and resist-
ance to azithromycin, and whole genome sequencing 
analysis revealed an amino acid substitution in riboso-
mal protein L22 (leading to azithromycin resistance), 
but no mutations in the 23S rRNA gene, which explains 
the susceptibility to erythromycin [38]. Further analyses 
are needed to determine the genomic background being 
responsible for the divergent MIC distributions observed 
by us for Arcobacter spp.
As mentioned before, 86% of the investigated Arcobac-
ter isolates showed low MICs for ciprofloxacin ranging 
from 0.032–0.50  µg/ml, which is further supported by 
a recent study reporting ciprofloxacin susceptibility for 
all tested Arcobacter butzleri isolates [36]. In contrast, 
clinical Campylobacter isolates displayed high resistance 
rates (MICs ≥ 4 µg/ml) ranging from 45 to 71.4% [39, 40]. 
Notably, we found elevated MICs for ciprofloxacin pre-
dominantly in A. cryaerophilus strains similar to a Bel-
gian study [34]. Thus, ciprofloxacin might be the drug of 
choice, if antibiotic treatment of A. butzleri-infection is 
required.
In accordance with our data, only low resistance rates 
from 0–4% of Arcobacter spp. to gentamicin have been 
reported before [36]. Similarly, susceptibility to tetracy-
cline might be common, although one recent study from 
retail food in Portugal demonstrated high resistance 
(95%) in A. butzleri [5, 41]. Furthermore, 42% of our A. 
butzleri isolates displayed high MICs for ampicillin (24–
64 µg/ml), which is similar to previous studies where 50 
to 100% isolates with high ampicillin MICs have been 
shown [20, 22, 31, 34].
Table 2 MIC distribution for 24 A. butzleri, 10 A. cryaerophilus and 2 A. lanthieri isolates
a The maximum concentration tested by the ciprofloxacin gradient strip was 32 µg/ml. MIC > 32 µg/ml indicate no growth inhibition
Antimicrobial agent Species  No. of strains with MIC (µg/ml) of:
0.032 0.064 0.125 0.25 0.50 1 2 4 8 16 32 (> 32) 64 128
Azithromycin A. butzleri 2 2 7 1 8 3 1
A. cryaerophilus 8 1 1
A. lanthieri 2
Ampicillin A. butzleri 1 1 4 4 4 8 2
A. cryaerophilus 3 4 1 2
A. lanthieri 1 1
Ciprofloxacina A. butzleri 1 2 8 11 1 1
A. cryaerophilus 4 2 1 3
A. lanthieri 2
Gentamicin A. butzleri 8 16
A. cryaerophilus 2 5 3
A. lanthieri 2
Erythromycin A. butzleri 1 2 8 11 1 1
A. cryaerophilus 4 6
A. lanthieri
Tetracycline A. butzleri 5 17 2
A. cryaerophilus 1 4 5
A. lanthieri 1 1
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Conclusions
In summary, Arcobacter spp. were not rare in our study 
and could be isolated more often from outpatients than 
from hospitalized patients. Furthermore, A. lanthieri was 
identified in fecal samples from human patients for the 
first time. Results from antimicrobial susceptibility test-
ing indicate that Arcobacter spp. might be more suscep-
tible to fluoroquinolones than to macrolides, particularly 
azithromycin. Future studies should provide reliable risk 
assessments of Arcobacter infections in humans.
Methods
Isolation of Arcobacter spp
During a 13-month survey (from October 2017 until 
October 2018) 4636 stool samples were collected at three 
microbiological diagnostic laboratories in Berlin, Ger-
many. Only stool samples submitted for the detection 
of bacterial enteropathogens were included. Given that 
samples were pseudonymized before performance, no 
detailed patient information were available. Samples were 
stored up to 1 week at 4 °C by the diagnostic laboratories 
until Arcobacter specific isolation procedures were per-
formed in our laboratories.
For detection of Arcobacter spp., isolation was car-
ried out using selective enrichment media according to 
a study done by van Driessche et al. [16]. All incubation 
steps were performed at 30 °C under microaerobic condi-
tions unless stated differently. Briefly, 1 g of stool samples 
was diluted at 1:10 with Arcobacter broth (Oxoid, Wesel, 
Germany) (24  g/l) containing 5% lysed horse blood, 
5´-fluorouracil (100  mg/l), amphotericin B (10  mg/L), 
novobiocin (32  mg/l), cefoperazone (16  mg/l) and tri-
methoprim (64  mg/l) (Sigma-Aldrich, Taufkirchen, 
Germany). The samples were mixed thoroughly, and 
incubated for 72 h. Samples were then plated onto Arco-
bacter selective plates (as described above except lysed 
horse blood) and incubated for 48  h. Suspect colonies 
(i.e., small round white or grey colonies) were transferred 
onto Mueller–Hinton agar plates (Oxoid) supplemented 
with 5% sheep blood (MHB) and incubated for 48 h.
PCR analyses
The genomic DNA of these isolates was extracted by 
using a modified chelex-based method described by 
Karadas et  al. [17]. Briefly, a small amount of colony 
material was washed in 250  µl TE buffer (1  mM Tris/
HCL, pH 8.0, 100 µM EDTA; Roth, Karlsruhe, Germany) 
and pelleted by centrifugation at 16,000×g for 6  min. 
Pellets were resuspended in 250  µl 5% Chelex (BioRad, 
Munich, Germany) followed by incubation at 56  °C for 
1 h and subsequently at 95 °C for 10 min. After centrifu-
gation at 16,000xg for 5  min, 100  µl of the supernatant 
were stored at 4 °C or directly used to identify the isolates 
by multiplex PCR according to Houf et  al. [18]. Briefly, 
PCR reaction mixture contained 1x PCR buffer (Qiagen, 
Venlo, Netherlands), 2.8  mM  MgCl2 (Qiagen), 0.2  mM 
of each deoxynucleoside triphosphate (dNTP) (Thermo 
Fisher Scientific, Waltham, USA), 0.75 U Taq polymer-
ase (Qiagen), 1  µM of each primer ARCO R, BUTZ F, 
CRY 1, and CRY 2 and 0.5 µM of primer SKIR F, and 2 µl 
template DNA in a total reaction volume of 25  µl. PCR 
samples were subjected to an initial denaturation step 
at 94  °C for 5  min, followed by 32 amplification cycles, 
consisting of denaturation at 94 °C for 45 s, annealing at 
61 °C for 45 s and elongation at 72 °C for 30 s, and subse-
quently 5 min at 72 °C for final extension. DNA of A. but-
zleri (CCUG 30485), A.  cryaerophilus (DSM 7289) and 
A. skirrowii (CCUG 10374) were used as control. Ampli-
fied products were separated using gel electrophoresis 
and visualized under UV light by GRgreen staining.
For verification at species level, all positive isolates 
were analyzed by rpoB sequencing according to a study 
done by Korczak et al. [19]. Briefly, a 50 µl PCR-mixture 
contained 4  µl template DNA, 1x  PCR  buffer, 2.5  mM 
 MgCl2, 0.2 mM of each dNTP, 1 U Taq polymerase and 
0.4  µM of each primer CamrpoB-L and RpoB-R. PCR 
reaction conditions were 95  °C for 3  min followed by 
35 cycles of 94  °C for 30 s, 54  °C for 30 s and 72  °C for 
30 s and subsequently a final extension step at 72 °C for 
7 min. Amplified products were separated using gel elec-
trophoresis and visualized under UV light by GRgreen 
staining. Amplicons were purified using GeneJET PCR 
Purification Kit (Thermo Fisher Scientific) according to 
the manufacturer’s instructions and sequenced by GATC 
(Eurofins GATC Biotech, Konstanz, Germany). Species 
were identified by comparing the rpoB sequences with 
BLAST database (NCBI).
Antimicrobial susceptibility testing
Susceptibility testing of Arcobacter spp. isolates to azithro-
mycin, ampicillin, ciprofloxacin, gentamycin, erythromycin 
and tetracycline was performed using the gradient strip 
diffusion method (E-testTM, bioMérieux, Nürtingen, Ger-
many). Briefly, Arcobacter isolates grown on MHB agar 
plates (30  °C, microaerobic, 48  h) were precultured over-
night in brucella broth (BB; 30  °C, microaerophilic) to 
receive an inoculum of approximately 1 x 108 colony form-
ing units (CFU) per ml. Escherichia coli ATCC 25922 was 
used as control and cultured likewise, but at 37 °C and in 
aerobic atmosphere. For testing the slower growing A. 
cryaerophilus isolates, three overnight cultures per iso-
late were pooled (6 ml), centrifuged, and the pellets resus-
pended in 600 µl BB in order to receive similar inoculum 
concentrations. MHB agar plates were inoculated with 
100  µl of preculture and incubated after application of 
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gradient strips at 30 °C for 48 h under microaerobic condi-
tions (37 °C and aerobic for E. coli).
Statistical analysis
For calculating significant differences in prevalences of 
Arcobacter in outpatients and hospitalized patients, the 
Chi squared test and the Fisher’s exact test were performed 
using GraphPad Prism (version 5.04; GraphPad Software, 
Inc., La Jolla, US). Differences were considered significant 
at values of P < 0.05.
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